专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明授权

US5182099A Preparation for prevention of emission of mercury from amalgam fillings and method 失效
标题翻译：汞合金填料防止汞排放的准备和方法
公开(公告)号：US5182099A
公开(公告)日：1993-01-26
申请号：US750474
申请日：1991-08-27
申请人： Eston Jonsson , Roland Waern
发明人： Eston Jonsson , Roland Waern
IPC分类号： A61K6/00 , A61K8/23 , A61Q11/00 , G01N33/15
CPC分类号： A61Q11/00 , A61K6/0008 , A61K6/0023 , A61K8/23 , Y10S514/922 , Y10S514/974
摘要： A method of preventing or decreasing the emission of mercury vapor in the mouth, from a mercury amalgam filling, comprising contacting the amalgam filling with an oral composition containing sulfur in an amount sufficient to reduce or eliminate the emission of mercury or mercury vapor. The oral composition may be in the form of a toothpaste, chewing gum, mouthwash water, mouth spray, or the like.
摘要翻译：一种防止或减少从汞汞齐填充物中口腔内汞蒸汽排放的方法，包括使汞齐填充物与含硫量的口服组合物接触，其量足以减少或消除汞或汞蒸气的排放。口腔组合物可以是牙膏，口香糖，漱口水，口腔喷雾剂等的形式。

52. 发明授权

US5171563A Cleavable linkers for the reduction of non-target organ retention of immunoconjugates 失效
标题翻译：用于减少免疫缀合物的非目标器官保留的可切割接头
公开(公告)号：US5171563A
公开(公告)日：1992-12-15
申请号：US830973
申请日：1992-02-10
申请人： Paul G. Abrams , John M. Reno , Alan R. Fritzberg , Ananthachari Srinivasan , David C. Anderson
发明人： Paul G. Abrams , John M. Reno , Alan R. Fritzberg , Ananthachari Srinivasan , David C. Anderson
IPC分类号： A61K47/48 , A61K51/08 , A61K51/10
CPC分类号： A61K47/48338 , A61K51/088 , A61K51/1093 , A61K2121/00 , A61K2123/00 , Y10S514/836 , Y10S514/922 , Y10S530/807
摘要： A process for reducing the non-target organ accumulation of immunoconjugates administered in vivo during therapeutic or diagnostic procedures involves the use of immunoconjugates comprising linkers that are cleavable at the non-target organs. The linkers are cleavable under conditions present, or induced, at one or more non-target organs, which include the kidneys or the liver.
摘要翻译：在治疗或诊断过程中减少在体内施用的免疫缀合物的非靶器官积累的方法涉及使用包含在非靶器官可切割的接头的免疫缀合物。接头可在包括肾脏或肝脏的一个或多个非靶器官存在或诱导的条件下切割。

53. 发明授权

US5035878A Use of dithiocarbamates to counteract myelosuppression 失效
标题翻译：使用二硫代氨基甲酸盐来抵抗骨髓抑制
公开(公告)号：US5035878A
公开(公告)日：1991-07-30
申请号：US418549
申请日：1989-10-10
申请人： Richard F. Borch , Therese K. Schmalbach
发明人： Richard F. Borch , Therese K. Schmalbach
IPC分类号： A61K31/27 , A61K38/00 , C07K14/53 , C12N5/077
CPC分类号： C12N5/0669 , A61K31/27 , C07K14/53 , A61K38/00 , C12N2501/999 , Y10S514/823 , Y10S514/885 , Y10S514/922
摘要： Various types of biological treatments, including antineoplastic treatments with antineoplastic drugs, can result in damage to the blood-forming function of the bone marrow. This damage can be reversed, at least to some degree, with an effective amount (preferably an extremely low dose) of a pharmaceutically acceptable dithiocarbamic compound, including a compound of the formula R.sub.1 R.sub.2 NCSSM or R.sub.1 R.sub.2 NCSS-SCSNR.sup.3 R.sup.4, wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are the same or different aliphatic or cycloaliphatic or heterocycloaliphatic groups, unsubstituted or substituted by hydroxyl, or one of R.sup.1 and R.sup.2 and one of R.sup.3 and R.sup.4 can be H, or R.sup.1 and R.sup.2 or R.sup.3 and R.sup.4, taken together with the N atom upon which the pair of R groups is substituted, can be a 5- or 6-member N-heterocyclic ring which is aliphatic or aliphatic interrupted by a ring oxygen or second ring nitrogen, and M is H or one equivalent of a pharmaceutically acceptable cation, in which case the rest of the molecule is negatively charged. The dosage in mammals can range from about 0.001 to 30 mg/kg of body weight. For larger mammals, including humans, a typical dosage unit is less than 10 mg/kg, e.g.
摘要翻译：各种类型的生物处理，包括抗肿瘤药物的抗肿瘤治疗可能会损害骨髓的血液形成功能。至少在某种程度上可以使用有效量（优选极低剂量）的药学上可接受的二硫代氨基甲酸酯化合物，包括式R1R2NCSSM或R1R2NCSS-SCSNR3R4的化合物，其中R 1，R 2，R 3和 R4是相同或不同的未取代或被羟基取代的脂族或脂环族或杂脂肪族基团，或R 1和R 2之一，R 3和R 4中的一个可以是H，或者R 1和R 2或R 3和R 4与N原子一起一对R基团被取代的基团可以是被环氧或第二环氮中断的脂族或脂族的5-或6-元N-杂环，M是H或一当量的药学上可接受的阳离子在这种情况下，分子的其余部分是带负电荷的。哺乳动物的剂量可以为约0.001至30mg / kg体重。对于较大的哺乳动物，包括人类，典型的剂量单位小于10mg / kg，例如 <3 mg / kg。剂量单位可以溶解在合适的药学上可接受的载体（例如水性介质）中，然后优选在施用可引起骨髓损伤的药物的8小时内静脉内施用。在本发明中特别优选的极低剂量不会引起任何显着的副作用。

54. 发明授权

US5013540A Using NMDA receptor antagonists to reduce damage due to laser treatment 失效
标题翻译：使用NMDA受体拮抗剂减少激光治疗造成的损伤
公开(公告)号：US5013540A
公开(公告)日：1991-05-07
申请号：US444725
申请日：1989-11-30
申请人： Dianna A. Redburn
发明人： Dianna A. Redburn
IPC分类号： A61K31/00 , A61K31/485
CPC分类号： A61K31/00 , A61K31/485 , Y10S514/922
摘要： A method is disclosed for preventing the spread of damage in neuronal tissue that has been selectively burned by surgical laser treatment. Administration of an NMDA receptor blocker, such as dextrorphan, in conjunction with the laser treatment permits the site of the laser burn to be confined more precisely to the desired area, and prevents the spread of damage to surrounding tissue that would normally occur in the days after the laser treatment.
摘要翻译：公开了一种用于防止通过手术激光治疗选择性地烧伤的神经元组织中的损伤扩散的方法。 NMDA受体阻断剂如右旋糖苷配合激光治疗允许将激光烧伤部位更准确地限制在所需区域，并防止在日子中通常发生的对周围组织的损伤的扩散激光治疗后。

55. 发明授权

US5010092A Protection against chemically-induced kidney damage by methimazole 失效
标题翻译：通过甲巯咪唑防止化学诱导的肾损伤
公开(公告)号：US5010092A
公开(公告)日：1991-04-23
申请号：US454884
申请日：1989-12-22
申请人： Adnan A. Elfarra
发明人： Adnan A. Elfarra
IPC分类号： A61K31/195 , A61K31/198 , A61K31/415 , A61K31/545 , A61K31/555 , A61K31/70 , A61K33/24 , A61K51/00 , A61P13/02 , A61P15/00 , A61P39/02
CPC分类号： A61K31/415 , Y10S514/869 , Y10S514/922
摘要： Drug treatment therapies and kits for use therewith are disclosed. They involve the use of methimazole and/or its pro-drug carbimazole to reduce nephrotoxic effects of chemical exposure. In one embodiment, a patient receives cisplatin and then is treated with methimazole. The time delay in providing methimazole prevents the methimazole from being substantially expelled by the kidney prior to cisplatin reaching the kidney.

56. 发明授权

US4994261A Pesticide compositions and method 失效
标题翻译：农药组合物和方法
公开(公告)号：US4994261A
公开(公告)日：1991-02-19
申请号：US232193
申请日：1988-08-15
申请人： Herbert B. Scher , Marius Rodson , Ronald L. Morgan
发明人： Herbert B. Scher , Marius Rodson , Ronald L. Morgan
IPC分类号： A01N25/12 , A01N25/22 , A01N25/32 , A01N57/12 , A01N57/22
CPC分类号： A01N57/12 , A01N25/12 , A01N25/22 , A01N25/32 , A01N57/22 , Y10S514/922 , Y10S514/974
摘要： Toxicant, especially pesticide compositions, having lowered dermal toxicity are provided. The compositions include a lipophilic-pesticide, a nonionic surfactant and a dry inert diluent carrier. Methods for reducing the dermal toxicity of lipophilic toxicants, especially pesticides are provided, as well as methods for controlling insect pests using the disclosed compositions.
摘要翻译：提供具有降低的皮肤毒性的毒性，特别是农药组合物。组合物包括亲脂性农药，非离子表面活性剂和干惰性稀释剂载体。提供了降低亲脂性毒物特别是农药的皮肤毒性的方法，以及使用所公开的组合物来控制害虫的方法。

57. 发明授权

US4983621A Medicaments 失效
标题翻译：药剂
公开(公告)号：US4983621A
公开(公告)日：1991-01-08
申请号：US375913
申请日：1989-07-06
申请人： Keith T. Bunce , Patrick P. A. Humphrey
发明人： Keith T. Bunce , Patrick P. A. Humphrey
IPC分类号： C07D403/06 , A61K31/415 , A61K31/53 , A61K31/54 , A61K31/60 , A61K45/06 , A61P1/08 , A61P43/00
CPC分类号： A61K31/53 , A61K31/415 , A61K31/54 , A61K31/60 , A61K45/06 , Y10S514/872 , Y10S514/922
摘要： The invention relates to the co-administration in human or veterinary medicine of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one or a physiologically acceptable salt or solvate thereof and a cyclo-oxygenase inhibitor such as indomethacin or piroxicam.The two active ingredients, which may be administered separately either simultaneously or sequentially, or may be combined in a single pharmaceutical preparation, are useful in the relief and/or prevention of nausea and vomiting.
摘要翻译：本发明涉及人或兽医学中1,2,3,9-四氢-9-甲基-3 - [（2-甲基-1H-咪唑-1-基）甲基] -4H-咔唑的共同给药 -4-酮或其生理学上可接受的盐或溶剂合物和环加氧酶抑制剂如吲哚美辛或吡罗昔康。可以单独或依次单独施用或可以组合在单一药物制剂中的两种活性成分可用于缓解和/或预防恶心和呕吐。

58. 发明授权

US4961926A Methods for prevention and treatment of mucositis with granulocyte colony stimulating factor 失效
标题翻译：用粒细胞集落刺激因子预防和治疗粘膜炎的方法
公开(公告)号：US4961926A
公开(公告)日：1990-10-09
申请号：US122784
申请日：1987-11-19
申请人： Janice L. Gabrilove
发明人： Janice L. Gabrilove
IPC分类号： A61K38/00 , A61N5/10 , A61P1/02 , A61P17/00 , C07K14/535 , C12P21/02
CPC分类号： C07K14/535 , Y10S514/917 , Y10S514/922
摘要： This invention provides method of preventing mucositis in a subject susceptible to mucositis comprising administering to the subject a prophylactically effective amount of granulocyte colony stimulating factor or a polypeptide analog thereof having substantially the same amino acid sequence and the activity of naturally occurring granulocyte colony stimulating factor. This invention further provides a method of treating mucositis in a subject having mucositis comprising administering to the subject a therapeutically effective amount of granulocyte colony stimulating factor or a polypeptide analog thereof having substantially the same amino acid sequence and the activity of naturally occurring granulocyte colony stimulating factor.
摘要翻译：本发明提供了防止易于粘膜炎的受试者的粘膜炎的方法，其包括给予受试者预防有效量的具有基本上相同氨基酸序列和天然存在的粒细胞集落刺激因子的活性的粒细胞集落刺激因子或其多肽类似物。本发明进一步提供一种治疗患有粘膜炎的受试者的粘膜炎的方法，其包括向受试者施用治疗有效量的具有基本上相同氨基酸序列和天然存在的粒细胞集落刺激因子的活性的粒细胞集落刺激因子或其多肽类似物。

59. 发明授权

US4950465A Pharmaceutical composition for relieving side effects of platinum-containing drugs 失效
标题翻译：用于缓解含铂药物副作用的药物组合物
公开(公告)号：US4950465A
公开(公告)日：1990-08-21
申请号：US307686
申请日：1989-02-07
申请人： Toshio Sato , Yoshinosuke Fukuchi , Kenji Toba
发明人： Toshio Sato , Yoshinosuke Fukuchi , Kenji Toba
IPC分类号： A61K33/24 , A61K38/00 , A61K38/17 , A61K38/55 , A61P35/00 , A61P43/00
CPC分类号： A61K33/24 , A61K38/005 , A61K38/1709 , Y10S514/922
摘要： A pharmaceutical composition for relieving side effects of platinum-containing drugs, containing an effective component of ulinastatin is provided. The platinum-containing drugs such as cisplatinum cause serious side effects including kidney dysfunction. The kidney dysfunction, particularly the one caused by a disorder or uriniferous tubule may be significantly relieved by administering the ulinastatin-containing agent of the present invention.

60. 发明授权

US4917881A Dehydrated garlic preparations and buffer compounds to alleviate digestively induced aftereffects 失效
标题翻译：脱水大蒜制剂和缓冲化合物，以缓解消化诱导的后遗症
公开(公告)号：US4917881A
公开(公告)日：1990-04-17
申请号：US164191
申请日：1988-03-04
申请人： Daniel S. Gray
发明人： Daniel S. Gray
IPC分类号： A61K33/32 , A61K36/8962
CPC分类号： A61K36/8962 , Y10S514/922
摘要： There is disclosed a unique composition which essentially comprises a granule or cell or garlic having adhered thereto a suitable amount of zinc oxide. The zinc oxide acts as a buffer to alleviate the unpleasant aftereffects which are cused by the ingestion or consumption of garlic. In this manner zinc oxide functions to digestively avoid such unpleasant aftereffects associated with the ingestion or consumption of garlic.
摘要翻译：公开了一种独特的组合物，其基本上包含粘附有适量氧化锌的颗粒或细胞或大蒜。氧化锌作为缓冲剂，以缓解由大蒜摄入或消耗而引起的不愉快的后果。以这种方式，氧化锌起消化作用以避免与摄取或消耗大蒜相关的这种不愉快的后果。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式